pyrazines has been researched along with etp-46321 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguirre, E; Albarrán, M; Alfonso, P; Barbacid, M; Bischoff, JR; Cebrián, D; Cendón, E; Fominaya, J; García-Serelde, B; Gomez-Casero, E; Gonzalez-Granda, T; Hernández, AI; Link, W; Lorenzo, M; Martín, JI; Martínez González, S; Mulero, F; Oyarzabal, J; Pastor, J; Pizcueta, P; Rabal, O; Ramos-Lima, F; Rivero, V; Rodríguez, A; Rodríguez-Arístegui, S; Saluste, CG; Varela, C | 1 |
| Albarran, MI; Alonso, P; Anguita, PV; Bischoff, JR; Cebriá, A; Cebrián, D; Fominaya, J; Granda, TG; Link, W; López, AR; López, EC; Lorenzo, M; Martínez, S; Merino, T; Palacios, I; Pastor, J; Peregrina, S; Serelde, BG | 1 |
| Acosta, YY; Aragoneses-Fenoll, L; Blanco-Aparicio, C; Criado, G; Dianzani, U; Herranz, J; Martínez, S; Montes-Casado, M; Ojeda, G; Pastor, J; Portolés, P; Rojo, JM | 1 |
| Albarrán, MI; Alfonso, P; Álvarez, RM; Bischoff, JR; Cebriá, A; Cebrián, D; Cendón, E; González Cantalapiedra, E; Hernández, AI; Martínez González, S; Pastor, J; Rodríguez Hergueta, A; Rodríguez-Arístegui, S; Varela, C | 1 |
| Albarrán, MI; Álvarez, RM; Bischoff, JR; Blanco-Aparicio, C; Cebriá, A; Cebrián, D; García-Arocha, J; Hernández, AI; Hernández-Encinas, E; Martínez González, S; Pastor, J; Ramos-Lima, F; Rodríguez, A | 1 |
5 other study(ies) available for pyrazines and etp-46321
| Article | Year |
|---|---|
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Topics: Administration, Oral; Biological Availability; Humans; Imidazoles; Isoenzymes; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazines; Tomography, X-Ray Computed | 2012 |
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2013 |
ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Topics: Animals; Antibodies; Arthritis, Experimental; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; Class Ia Phosphatidylinositol 3-Kinase; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Imidazoles; Interferon-gamma; Interleukin-10; Interleukin-2; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Phosphoinositide-3 Kinase Inhibitors; Protein Subunits; Proto-Oncogene Proteins c-akt; Pyrazines; T-Box Domain Proteins | 2016 |
Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
Topics: Animals; Half-Life; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Microsomes, Liver; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Isoforms; Protein Kinase Inhibitors; Pyrazines; Structure-Activity Relationship | 2017 |
Identification of novel PI3K inhibitors through a scaffold hopping strategy.
Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Drug Evaluation, Preclinical; Half-Life; Imidazoles; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases | 2017 |